CGEM Cullinan Oncology Inc

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will participate in the following investor conferences:

  • Chief Financial Officer Jeff Trigilio will present at the HC Wainwright Global Investment Conference on September 13, 2022 at 2:00 p.m. EDT
  • Chief Executive Officer Nadim Ahmed will participate in a fireside chat at the Morgan Stanley Healthcare Conference on September 14, 2022 at 10:35 a.m. EDT

Live webcasts of the HC Wainwright presentation and Morgan Stanley fireside chat will be available via the Events section of the Company’s investor relations website at .

About Cullinan Oncology

(Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.

Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at , and follow us on LinkedIn and Twitter.

Contacts:

Investor Relations

Chad Messer

+1 203.464.8900

Media

Rose Weldon

+1 215.801.7644



EN
07/09/2022

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
05/08/25 May 8, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Reports First Quar...

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical com...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 ...

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targe...

April 29, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 ...

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small ce...

April 23, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Receives Approval from European Medicines Agency...

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic t...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch